Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
María Laura Acosta-Felquer, Javier Rosa & Enrique R Soriano. (2016) An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatology: Research and Reviews 8, pages 37-44.
Read now
Read now
Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Mariko Kobayashi, Toshiharu Shoji, Osamu Togo, Nobuyuki Miyasaka & Takao Koike. (2016) analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Modern Rheumatology 26:4, pages 473-480.
Read now
Read now
Vicenç Torrente-Segarra, Ana Urruticoechea Arana, Amalia Sánchez-Andrade Fernández, Juan Víctor Tovar Beltrán, Alejandro Muñoz Jiménez, Anna Martínez-Cristóbal, José Antonio González Ferrández, Manuel Fernández Prada, Noelia Vázquez Fuentes, Hèctor Corominas, Sílvia García-Díaz, Asunción Acosta Pereira, José Miguel Ruiz Martín, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, Desireé Ruiz Vilchez, Raúl Veiga Cabello, Jesús Carlos Fernández, José Raúl Noguera Pons, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, Raúl Cortés Verdú, Angel Aragón Díez, Carlos Tomás Roura, Concepción Moll Turudi, Delia Taverner Torrent, Felipe Joaquín Rivas Santirso, Juan José Lerma Garrido, Rosa García Portales, Sergi Ordoñez Palau, Silvia Paredes González-Albo, Antonio Gracia Pérez, Arantxa Conesa Mateos, Jaime Calvo Alén, Jenaro Graña Gil, María Pilar Navarro Alonso & María Jesús Martínez Blasco. (2016) study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. Modern Rheumatology 26:3, pages 336-341.
Read now
Read now
Renata Baronaite Hansen & Arthur Kavanaugh. (2015) Certolizumab pegol for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 11:3, pages 307-318.
Read now
Read now
Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Nobuyuki Miyasaka & Takao Koike. (2015) Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Modern Rheumatology 25:1, pages 11-20.
Read now
Read now
Articles from other publishers (30)
Shinya Hagiwara, Hiroto Tsuboi, Yuki Kuroda, Tomonori Sawabe, Nana Uematsu, Fumina Kawashima, Toshiki Sugita, Mayu Terasaki, Fumika Honda, Mizuki Yagishita, Yuya Kondo, Takayuki Sumida & Isao Matsumoto. (2023) Comparative analysis of low-field magnetic resonance imaging in patients with rheumatoid arthritis treated with certolizumab pegol or infliximab. Modern Rheumatology 33:6, pages 1097-1103.
Crossref
Crossref
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda & Désirée van der Heijde. (2023)
Post hoc
analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
. Modern Rheumatology 33:1, pages 73-80.
Crossref
Crossref
Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki & Tsutomu Takeuchi. (2022) Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Modern Rheumatology.
Crossref
Crossref
Mengduan Pang, Zhe Sun & Hongfeng Zhang. (2022) Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis. Medicine 101:32, pages e29838.
Crossref
Crossref
Hideto Kameda, Keiichiro Nishida, Toshihiro Nanki, Akira Watanabe, Yukiya Oshima & Shigeki Momohara. (2022) Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study. Modern Rheumatology.
Crossref
Crossref
Eri Sugano, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Mai Abe, Kumiko Saka, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka & Masayoshi Harigai. (2022) Differences in patients’ population and efficacy/effectiveness of biologic disease–modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis – using the IORRA cohort. Modern Rheumatology 32:4, pages 675-685.
Crossref
Crossref
Yoshiya Tanaka, Hiroyuki Okumura, Soyoung Kim, Julie Dorey, Piotr Wojciechowski, Justyna Chorąży, Daisuke Kato & Neil M. Schultz. (2021) Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. Rheumatology and Therapy 8:2, pages 729-750.
Crossref
Crossref
Yuji Nozaki, Toshihiko Hidaka, Jinhai Ri, Tetsu Itami, Daisuke Tomita, Akinori Okada, Chisato Ashida, Fusayo Ikeda, Atsuhiro Yamamoto, Keiko Funahashi, Koji Kinoshita, Tsukasa Matsubara, Masanori Funauchi & Itaru Matsumura. (2021) Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis. Frontiers in Medicine 8.
Crossref
Crossref
Gerlienke E. Geurts-Voerman, Lise M. Verhoef, Bart J. F. van den Bemt & Alfons A. den Broeder. (2020) The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence. BMC Rheumatology 4:1.
Crossref
Crossref
Yune-Jung Park, Ana Maria Gherghe & Desirée van der Heijde. (2020) Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry. RMD Open 6:2, pages e001277.
Crossref
Crossref
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Kou Katayama, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Teruaki Shiomi, Emi Yamada & Désirée van der Heijde. (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid
arthritis and an inadequate response to methotrexate: results of a phase III
randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases 78:10, pages 1305-1319.
Crossref
Crossref
Niels Graudal, Benjamin Skov Kaas-Hansen, Louise Guski, Thorbjørn Hubeck-Graudal, Nicky J. Welton & Gesche Jürgens. (2019) Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials. International Journal of Molecular Sciences 20:18, pages 4350.
Crossref
Crossref
Ernest Choy, Nick Freemantle, Clare Proudfoot, Chieh-I Chen, Laurence Pollissard, Andreas Kuznik, Hubert Van Hoogstraten, Erin Mangan, Paulo Carita & Thi-Minh-Thao Huynh. (2019) Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open 5:1, pages e000798.
Crossref
Crossref
Paul Emery, Janet E. Pope, Klaus Kruger, Ralph Lippe, Ryan DeMasi, Sadiq Lula & Blerina Kola. (2018) Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. Advances in Therapy 35:10, pages 1535-1563.
Crossref
Crossref
Enrique R Soriano, Analia Dellepiane, Gabriela Salvatierra, Cristian Alejandro Benítez, Rodrigo Garcia Salinas & Carlos Baruzzo. (2018) Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Science OA 4:4, pages FSO289.
Crossref
Crossref
Iñigo Bermejo, Matt Stevenson, Rachel Archer, John W. Stevens, Edward Goka, Mark Clowes, David L. Scott & Adam Young. (2017) Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 35:11, pages 1141-1151.
Crossref
Crossref
Vicente Ruiz Garcia, Amanda Burls, Juan B Cabello, Paloma Vela Casasempere, Sylvia Bort-Marti & José A Bernal. (2017) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2017:9.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell & George A Wells. (2017) Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell & George A Wells. (2017) Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Hideto KAMEDA, Keiichiro NISHIDA, Toshihiro NANNKI, Akira WATANABE, Yukiya OSHIMAShigeki MOMOHARA. (2017) Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance. Japanese Journal of Clinical Immunology 40:3, pages 196-205.
Crossref
Crossref
Roy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, Derek H Tang, James Chung, David Collier, Shilpa Urs, Kerigo Ndirangu, George Wells & Janet Pope. (2017) Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open 3:1, pages e000371.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell & George A Wells. (2016) Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref
Fawziah Marra, Elaine Lo, Viktor Kalashnikov & Kathryn Richardson. (2016) Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases 3:4.
Crossref
Crossref
Yehong Wang, Rui Zhu, Jim Xiao, John C. DavisJrJr, Jaap W. Mandema, Jin Y. Jin & Meina T. Tang. (2015) Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis. The Journal of Clinical Pharmacology 56:7, pages 835-844.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell & George A Wells. (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Tsuyoshi TAKEDA. (2016) Treatment strategy of elderly rheumatoid arthritis. Japanese Journal of Clinical Immunology 39:6, pages 497-504.
Crossref
Crossref
Tatsuya Atsumi, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Shinsuke Yasuda, Yuji Yamanishi, Yasuhiko Kita, Tsukasa Matsubara, Masahiro Iwamoto, Toshiharu Shoji, Toshiyuki Okada, Désirée van der Heijde, Nobuyuki Miyasaka & Takao Koike. (2016) The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases 75:1, pages 75-83.
Crossref
Crossref
Alice Capogrosso Sansone, Stefania Mantarro, Marco Tuccori, Elisa Ruggiero, Sabrina Montagnani, Irma Convertino, Alessandra Marino, Matteo Fornai, Luca Antonioli, Tiberio Corona, Danila Garibaldi & Corrado Blandizzi. (2015) Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Safety 38:10, pages 869-888.
Crossref
Crossref
Akito Nishimura, Yohjiroh Minegishi, Keiko Kwamura, Asako Ichino & Katsufumi Uchiyama. (2015) Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis. Rheumatology International 35:9, pages 1601-1602.
Crossref
Crossref
Peter Y Shane & Sadayoshi Onodera. (2014) Novel TNF^|^alpha; inhibitor, certolizumab pegol. Drug Delivery System 29:2, pages 160-165.
Crossref
Crossref